Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $46.75M
• Dividend Yield: N/A
• Average Volume (3M): 899.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: 5489.03%
• EPS Growth: 86.23%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 86,389,100
• 10 Day Avg. Volume: 819,624
• 30 Day Avg. Volume: 899,857
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.20
• Enterprise Value/Revenue: -0.49
• Enterprise Value/Gross Profit: -0.51
• Enterprise Value/Ebitda: 4.33
• 1Y Price Target: $2.00
• Price Target Upside: 270.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 40 Underperform
• Price Target: $0.50 ▼(-7.41% Downside)

Century Therapeutics faces significant challenges with ongoing operational losses and negative cash flow, despite strong revenue growth and a solid balance sheet. The recent workforce reduction highlights financial strain. Technical indicators suggest bearish momentum, and the negative P/E ratio reflects the company's unprofitability.

Positive Factors

Clinical Progress

Century expects to report initial data from the CALiPSO-1 trial, indicating progress in its clinical trials.

Financial Stability

The company's cash runway has been extended into the fourth quarter of 2027, providing financial stability for future operations.

Pipeline Development

The ongoing IND-enabling studies for CNTY-308 and plans to advance it into the clinic show a commitment to expanding the therapeutic pipeline.

Negative Factors

Competitive Landscape

The 15-month lag between CALiPSO-1’s IND clearance and the dosing of the first patient likely reflects the increasingly competitive clinical trial landscape.

Data Interpretability

Several factors, such as diverse autoimmune indications and geographic diversity, could reduce the interpretability of the first CNTY-101 data read-out.

Regulatory Risk

There is an inability to secure regulatory approval for investigational therapies, notably CNTY-101.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics is a biotechnology company focusing on developing innovative cell therapies to treat cancer. The company is at the forefront of utilizing induced pluripotent stem cells (iPSCs) to create allogeneic, or 'off-the-shelf,' cell therapies. Century Therapeutics aims to develop products that effectively target and eliminate cancer cells, thereby providing transformative treatment options for patients.

How the Company Makes Money

Century Therapeutics generates revenue through the development and commercialization of its proprietary cell therapy products. The company primarily focuses on clinical-stage therapies, which involve significant research and development investments. Revenue streams may include licensing agreements, partnerships with pharmaceutical companies, and potential future sales of approved therapies. Additionally, strategic collaborations with other biotech companies or institutions can provide funding and shared resources, contributing to Century Therapeutics' earnings. As the therapies advance through clinical trials and gain regulatory approval, commercial sales are expected to become a significant revenue source.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics shows significant revenue growth but continues to operate at a net loss with negative EBIT and EBITDA margins. The balance sheet is strong with a high equity ratio and cash reserves, but cash flow is negative, indicating operational inefficiencies.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	114.13M	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	110.93M	6.59M	2.23M	-4.87M	-4.58M	-1.75M
EBITDA	-12.98M	-111.47M	-121.21M	-119.34M	-89.92M	-51.44M
Net Income	-23.28M	-126.57M	-136.67M	-130.93M	-95.82M	-54.66M
Balance Sheet
Total Assets	284.69M	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	155.84M	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	51.48M	53.83M	48.17M	49.41M	23.46M	21.55M
Total Liabilities	74.79M	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	209.90M	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-114.44M	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-114.77M	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	130.27M	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	-209.00K	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.55, below the 50-day MA of 0.57, and below the 200-day MA of 0.76, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 56.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CELU	56 Neutral	$90.77M	―	-232.51%	―	138.11%	76.60%
Sector *	51 Neutral	$7.88B	-0.12	-39.83%	2.18%	21.38%	-1.56%
STTK	47 Neutral	$45.99M	―	-73.39%	―	-27.33%	34.66%
PASG	44 Neutral	$23.53M	―	-88.27%	―	―	32.57%
IPSC	40 Underperform	$46.75M	―	-10.78%	―	5489.03%	86.23%
JSPR	35 Underperform	$47.62M	―	-146.87%	―	―	-17.96%

Century Therapeutics Corporate Events

Century Therapeutics Reports Q2 Results and Leadership Change

On August 14, 2025, Century Therapeutics announced its second quarter financial results and business updates, highlighting ongoing patient dosing in the CALiPSO-1 trial and progress in IND-enabling studies for CNTY-308. The company extended its cash runway into the fourth quarter of 2027 following a workforce reduction and strategic focus on high-potential programs. CEO Brent Pfeiffenberger was appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor. The company remains on track to report clinical data for CNTY-101 by the end of 2025 and plans to initiate clinical studies for CNTY-308 in 2026.

Century Therapeutics Announces Major Workforce Reduction

On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.

Century Therapeutics Holds 2025 Annual Stockholders Meeting

On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.